Skip to content
Open access

Transarterial Radioembolization Versus Chemoembolization for Unresectable Large Single Hepatocellular Carcinoma

Sep 2026 · Korean Journal of Radiology · Vol 27, pp. 961 - 972 · 0 citations · 26 references
Medicine

TL;DR

In patients with unresectable large solitary HCCs, TARE was associated with longer OS, improved local tumor control, and fewer serious adverse events than TACE, however, the survival advantage should be interpreted with caution.

Abstract

Objective To compare oncologic outcomes and safety between transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with unresectable large solitary hepatocellular carcinomas (HCCs; ≥6 cm). Materials and Methods This single-center retrospective study included patients with a solitary HCC ≥6 cm who underwent initial treatment with TARE or TACE between January 2010 and December 2023. Patients who were initially scheduled to undergo TARE but were subsequently treated with TACE because of a high lung shunt fraction (LSF) were included in the TACE group. The primary outcome was overall survival (OS), and secondary outcomes included progression-free survival (PFS), local PFS, tumor response, and safety. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline differences in the survival analyses. Results In total, 306 patients were included in this study (TACE, n = 187; TARE, n = 119). Before IPTW adjustment, the TARE group demonstrated significantly longer OS than the TACE group (median, 79.6 vs. 46.5 months; P = 0.004). Patients who were ineligible for TARE because of extensive lung shunting demonstrated particularly poor survival (median OS, 20.3 months). After IPTW adjustment, TARE remained associated with longer OS (median, 79.6 vs. 53.4 months; P = 0.033) and local PFS (median, 25.1 vs. 9.5 months; P = 0.001). Median PFS remained numerically longer with TARE (9.8 vs. 7.8 months), but the difference did not reach statistical significance (P = 0.066). In comparison with TACE, TARE was associated with less frequent serious adverse events (10.1% vs. 26.7%; P < 0.01) and a markedly lower rate of prolonged hospitalization (>7 days) (0.8% vs. 22.5%; P < 0.01). Conclusion In patients with unresectable large solitary HCCs, TARE was associated with longer OS, improved local tumor control, and fewer serious adverse events than TACE. However, the survival advantage should be interpreted with caution, because biological selection related to LSF eligibility may have contributed to the observed difference.

Read PDF

Similar papers

Open access Oct 2026

Preoperative radioembolization versus chemoembolization and upfront resection for resectable hepatocellular carcinoma beyond the Milan criteria.

BACKGROUND As the role of transarterial radioembolization (TARE) in resectable hepatocellular carcinoma (HCC) beyond Milan criteria remains undefined, this study compared preoperative TARE and chemoembolization (TACE) with primary resection to establish the optimal management strategy. MATERIALS AND METHODS We retros...

Jea-Yong Park, G. Lim, Yun-Mi Ko et al. · 0 citations
Oct 2026

Transarterial Radioembolization for Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria: A Single-Center Retrospective Cohort Study.

In this single-center retrospective cohort of patients with HCC beyond the Up-to-Seven criteria, favorable tumor control and survival outcomes were observed after TARE, and 22.3% of patients subsequently underwent curative-intent surgery.

T. W. Baek, Gun Ha Kim, Eunbyeol Ko et al. · 0 citations
Open access Oct 2026

Efficacy and safety of sintilimab plus bevacizumab with or without transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score-matched retrospective cohort study.

Background To compare the efficacy and safety of transarterial chemoembolization (TACE) plus sintilimab and bevacizumab (triple therapy) versus sintilimab and bevacizumab alone (dual therapy) in unresectable hepatocellular carcinoma (uHCC). Methods This single-center retrospective cohort study enrolled consecutive pa...

Zi-Zhuo Wang, Bai-Lu Wu, Chun-Shu Wu et al. · 0 citations
Open access Oct 2026

Sequential transarterial radioembolization and atezolizumab plus bevacizumab improves survival in advanced hepatocellular carcinoma.

BACKGROUND Yttrium-90 transarterial radioembolization (TARE) combined with immune checkpoint inhibitors has been investigated as a potential therapeutic strategy for advanced hepatocellular carcinoma (HCC); however, evidence supporting its addition to current standard systemic therapy remains limited. We aimed to compa...

Yun-Mi Ko, H. Shin, Moon-Haeng Hur et al. · 0 citations
Sep 2026

Impact of adjuvant transarterial chemoembolization on survival following hepatectomy for subcapsular hepatocellular carcinoma: A propensity score-matched study.

BACKGROUND Subcapsular hepatocellular carcinoma (HCC) is prone to postoperative recurrence, possibly related to tumor cell dissemination during surgery. Despite this high-risk feature, the role of routine postoperative adjuvant transarterial chemoembolization (TACE) remains controversial. This study evaluated adjuvant...

Q. Kong, Hao-Jia Wang, Jia-Hui Yang et al. · 0 citations
Open access Oct 2026

Enhanced Efficacy of Thalidomide‐Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi‐Center Cohort Study

ABSTRACT This retrospective study was designed to evaluate the safety and efficacy of adding a thalidomide‐based cocktail (the TCC cocktail—comprising thalidomide, carmofur, and compound mylabris capsule) to transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) in real‐world practice. D...

Jin-Zhi Xu, Li Song, Yi-Fan Kong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.